Study IDs Post-Transplant Anemia Contributors, Clarifies Role of ESAs
A systematic review and meta-analysis identified factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents (ESAs).
Related Articles
Impaired Kidney Function Predicts Hemorrhage Among Apixaban Users – Renal and Urology News
Investigators studied apixaban pharmacokinetics, pharmacodynamics, and hemorrhage risk by kidney function.
Why the US Needs Independent Kidney Care Guidelines for American Patients
A nephrologist argues that advancing kidney care in the US requires tailored guidelines addressing ethnic diversity & fragmented healthcare.
Kidney Pumping May Improve Long-Term Graft Survival – Renal and Urology News
Investigators studied the potential long-term benefits of kidney transplant machine perfusion.
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
“You absolutely need to have a CT scan prior to the surgery to best identify and really intimately understand the kidney’s anatomy,” says Perry Xu,…
2025 Annual Meeting – Las Vegas
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence…
Join and Save – AUA Annual Meeting
Become an AUA member and SAVE up to $886 on Annual Meeting registration!
Carl A. Olsson, MD: A True Legend and Friend | Urology Practice
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
What Is Needed to Support Nonurban Urology in the United States? Perspectives From Urologists in Rural and Underresourced Areas | Urology Practice
Introduction:Twenty percent of Americans live in nonurban areas, and the challenges in providing high-quality health care in rural areas are well described. These challenges are…
BWL plus ultrasonic propulsion shows safety, efficacy for small renal stones
Overall, 71% of patients had no fragment greater than 2 mm following treatment.
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Merrill discusses the evolving non–muscle invasive bladder cancer treatment space.